A Phase 1 interventional study of Alisertib in Advanced Solid Tumors, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-03-12.
Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purposes of this study were to estimate the relative (Rel) bioavailability (BA) of an oral solution (OS) formulation of alisertib in reference to a powder-in-capsule (PIC) formulation, to characterize the effect of food on the single-dose pharmacokinetics (PK) of alisertib OS and enteric-coated tablets (ECT), to characterize the multiple-dose safety, tolerability, and steady-state PK of alisertib administered as an OS, and to characterize the multiple-dose safety and tolerability of alisertib administered as an ECT.
The drug being tested in this study is called alisertib (MLN8237). Alisertib is being tested to treat people who have advanced solid tumors. This study will look at the relative bioavailability (BA) (Part A), food effect and multiple-dose PK and safety of the oral solution (OS) (Part B) and food effect and safety of the enteric-coated tablet (ECT) formulation (Part C).
The study enrolled 53 patients (pts). Prior to initiation of Part A, 4 participants were enrolled in a dose escalation cohort. Participants in the study received:
This multi-center trial was conducted in the United States. The overall time to participate in this study was 30 months. Participants made multiple visits to the clinic, and final assessments were performed approximately 30 days after last dose of study drug.
Millennium Pharmaceuticals, Inc. is the lead sponsor of 178 studies on the registry; none are open to participants now.
Of its 74 completed or terminated interventional studies of FDA-regulated products, 73 (99%) have results posted.
First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Each participant must meet all of the following inclusion criteria to be enrolled in the study:
Exclusion Criteria:
Participants meeting any of the following exclusion criteria are not to be enrolled in the study:
A medical condition requiring use of pancreatic enzymes; or daily, chronic , or regular use of proton pump inhibitors (PPI); or histamine (H2) receptor antagonists. Participants who intermittently use these medications must meet the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A single dose of alisertib 15 mg, oral solution (OS) was administered on Day 1, followed by alisertib 40 mg, powder-in-capsule (PIC), orally, twice a day (BID) on Days 3 through 9, followed by a 14-day rest period in Cycle 1 in a 23-day cycle. A single dose of alisertib 50 mg PIC, orally, was administered on Cycle 2 Day 1 followed by alisertib 40 mg on Days 3 through 9, followed by a 14-day rest period in Cycle 2 in a 23-day cycle. Subsequent cycles, alisertib 40 or 50 mg (individual dosage based on tolerability in Cycles 1 and 2), PIC, orally, BID on Days 1 through 7, followed by a 14-day rest period in 21-day cycles until disease progression, occurrence of an unacceptable alisertib-related toxicity, or the start of another anticancer therapy.
Drug: Alisertib
A single dose of alisertib 25 mg, OS, administered on Day 1, followed by alisertib 40 mg PIC, orally, BID on Days 3 through 9, followed by a 14-day rest period in Cycle 1, in a 23-day cycle. A single dose of alisertib 50 mg PIC, orally, administered on Cycle 2 Day 1, followed by alisertib 40 mg, PIC, orally, BID on Days 3 through 9, followed by a 14-day rest period in a 23-day cycle. Subsequent cycles, alisertib 40-50 mg (individual dosage based on tolerability in Cycles 1 and 2), PIC, orally, BID on Days 1 through 7, followed by a 14-day rest period in 21-day cycles until disease progression, occurrence of an unacceptable alisertib-related toxicity, or the start of another anticancer therapy.
Drug: Alisertib
A single dose of alisertib 50 mg, PIC, orally administered on Day 1, followed by alisertib 40 mg, PIC, orally, BID on Days 3 through 9, followed by a 14-day rest period in Cycle 1, in a 23-day cycle. Cycle 2 Day 1 alisertib 25 mg, OS, once on Day 1, followed by alisertib 40 mg, PIC, orally, BID on Days 3 through 9, followed by a 14-day rest period in a 23-day cycle. Subsequent cycles followed by alisertib 40-50 mg (individual dosage based on tolerability in Cycles 1 and 2), PIC, orally, BID on Days 1 through 7, followed by a 14-day rest period in Cycle 3, in 21-day cycles until disease progression, occurrence of an unacceptable alisertib-related toxicity, or the start of another anticancer therapy.
Drug: Alisertib
Alisertib 35 mg (35 mg = relative bioavailability estimate in Part A as dose of OS that was calculated to yield the area under the concentration time curve of a 50-mg PIC dose): A single dose of alisertib 35 mg oral solution (OS), in fed state, administered on Day 1, followed by alisertib 30 mg, OS, BID on Days 3-9, followed by a 14-day rest period in Cycle 1, in a 23-day cycle. Cycle 2 Day 1 alisertib 35 mg administered, OS, in fasted state, once on Day 1, followed by alisertib 30 mg, OS, BID on Days 3-9, followed by a 14-day rest period in a 23-day cycle. Cycle 3 onwards, participants received alisertib 40 mg, PIC, orally, BID on Days 1-7, with dose reduction to 30 mg BID or escalation to 50 mg BID permitted, based on individual tolerance, followed by a 14-day rest period, in 21-day cycles until disease progression, occurrence of an unacceptable alisertib-related toxicity, or the start of another anticancer therapy.
Drug: Alisertib
A single dose of alisertib 35 mg, OS, in fasted state, administered on Day 1, followed by alisertib 30 mg, OS, BID on Days 3-9, followed by a 14-day rest period in a 23-day cycle. Cycle 2 Day 1 alisertib 30 mg, OS administered in fed state, once on Day 1, followed by alisertib 30 mg, OS, BID on Days 3-9, followed by a 14-day rest period in a 23-day cycle. Cycle 3 onwards, participants received alisertib 40 mg PIC, orally, BID on Days 1-7, with dose reduction to 30 mg BID or escalation to 50 mg BID permitted based on individual tolerance, followed by a 14-day rest period in 21-day cycles until disease progression, occurrence of an unacceptable alisertib-related toxicity, or the start of another anticancer therapy.
Drug: Alisertib
Alisertib 50 mg, enteric-coated tablets (ECT), orally, in fed state, once on Day 1, followed by alisertib 40 mg, ECT, orally, BID on Days 3 through 9, followed by a 14-day rest period in Cycle 1 in a 23-day cycle, followed by alisertib 50 mg, ECT, orally, in fasted state, once on Day 1, followed by alisertib 40 or 50 mg, ECT, orally, BID on Days 3 through 9, followed by a 14-day rest period in Cycle 2 in a 23-day cycle. Cycle 3 onwards, participants were administered alisertib 40 mg BID ECT on Days 1-7 with dose reduction to 30 mg BID or escalation to 50 mg BID permitted based on individual tolerance, followed by a 14-day rest period in 21-day cycles until disease progression, occurrence of an unacceptable alisertib-related toxicity, or the start of another anticancer therapy.
Drug: Alisertib
Alisertib 50 mg, ECT, orally, in fasted state, once on Day 1, followed by alisertib 40 mg, ECT, BID on Days 3 through 9, followed by a 14-day rest period in Cycle 1 in a 23-day cycle, followed by alisertib 50 mg, ECT, orally, in fed state, once on Day 1, followed by alisertib 40 or 50 mg, ECT, orally, BID on Days 3 through 9, followed by a 14-day rest period in Cycle 2, a 23-day cycle. Cycle 3 onwards participants were administered alisertib 40 mg BID ECT on Days 1-7, with dose reduction to 30 mg BID or escalation to 50 mg BID permitted based on individual tolerance, followed by a 14-day rest period, in 21-day cycles until disease progression, occurrence of an unacceptable alisertib-related toxicity, or the start of another anticancer therapy.
Drug: Alisertib
Alisertib OS Alisertib PIC Alisertib PIC
Also known as: MLN8237
Part A: Dose-normalized Cmax (Maximum Observed Concentration) for Estimation of Relative Bioavailability for Alisertib Oral Solution (OS) Versus Powder in Capsule Formulations (PIC)
Dose normalized Cmax was obtained using Cmax divided by alisertib dose in milligrams to provide values adjusted to a 1 mg alisertib dose.
Time frame: Cycles 1 and 2 Day 1 predose and at multiple time points (up to 48 hours) postdose, and, if clinically feasible, at the time of a serious or unusual adverse event (AE) that was judged by the investigator to be treatment related.
Part A: Dose-normalized AUClast (Area Under the Concentration-Time Curve From Time 0 to Time of the Last Quantifiable Concentration) for Estimation of Relative Bioavailability for Alisertib Oral Solution (OS) Versus Powder in Capsule Formulations (PIC)
Dose normalized AUClast was obtained using Cmax divided by alisertib dose in milligrams to provide values adjusted to a 1 mg alisertib dose.
Time frame: Cycles 1 and 2 Day 1 predose and at multiple time points (up to 48 hours) postdose, and, if clinically feasible, at the time of a serious or unusual AE that was judged by the investigator to be treatment related.
Part B: Cmax: Maximum Observed Concentration for Alisertib Administered as an Oral Solution With Food Versus Without Food
Not performed.
Time frame: Cycles 1 and 2 Day 1 predose and at multiple time points (up to 48 hours) postdose, and, if clinically feasible, at the time of a serious or unusual AE that was judged by the investigator to be treatment related.
Part B: AUClast: Area Under the Concentration-Time Curve From Time 0 to Time of the Last Quantifiable Concentration for Alisertib Administered as an Oral Solution With Food Versus Without Food
Not performed.
Time frame: Cycles 1 and 2 Day 1 predose and at multiple time points (up to 48 hours) postdose, and, if clinically feasible, at the time of a serious or unusual AE that was judged by the investigator to be treatment related.
Part B: Cmax: Maximum Plasma Concentration for Alisertib Oral Solution Following Multiple-Dose Administration
Not performed.
Time frame: Cycle 1 Day 9 predose and at multiple time points (up to 12 hours) postdose, and, if clinically feasible, at the time of a serious or unusual AE that was judged by the investigator to be treatment related.
Part B: Tmax: Time of First Occurrence of Cmax Over the Dosing Interval for Alisertib Oral Solution Following Multiple-Dose Administration
Not performed.
Time frame: Cycle 1 Day 9 predose and at multiple time points (up to 12 hours) postdose, and, if clinically feasible, at the time of a serious or unusual AE that was judged by the investigator to be treatment related.
Part B: AUCτ: Area Under the Concentration-Time Curve From Time 0 to End of Dosing Interval for Alisertib Oral Solution Following Multiple-Dose Administration
Not performed.
Time frame: Cycle 1 Day 9 predose and at multiple time points (up to 12 hours) postdose, and, if clinically feasible, at the time of a serious or unusual AE that was judged by the investigator to be treatment related.
Part C: Cmax: Maximum Observed Concentration for Alisertib Administered as an Enteric-Coated Capsule (ECT) With Food Versus Without Food
Participants were randomized to receive 50-mg alisertib as an ECT (single, 50-mg strength tablets) under fasted or fed (following a standardized high-fat meal) conditions.
Time frame: Cycles 1 and 2 Day 1 predose and at multiple time points (up to 48 hours) postdose, and, if clinically feasible, at the time of a serious or unusual AE that was judged by the investigator to be treatment related.
Part C: AUClast: Area Under the Concentration-Time Curve From Time 0 to Time of the Last Quantifiable Concentration for Alisertib Administered as an Enteric-Coated Capsule (ECT) With Food Versus Without Food
Time frame: Cycles 1 and 2 on Day 1 predose and at multiple time points (up to 48 hours) postdose, and, if clinically feasible, at the time of a serious or unusual AE that was judged by the investigator to be treatment related.
Part C: AUC∞: Area Under the Concentration-Time Curve From Time 0 to Infinity, Calculated Using the Observed Value of the Last Quantifiable Concentration for Alisertib Administered as an Enteric-Coated Capsule (ECT) With Food Versus Without Food
Time frame: Cycles 1 and 2 on Day 1 predose and at multiple time points (up to 48 hours) postdose, and, if clinically feasible, at the time of a serious or unusual AE that was judged by the investigator to be treatment related.
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A Serious Adverse Event (SAE) A serious is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.
Time frame: Up to 30 days after the last dose of study drug (up to 27.4 months)
Number of Participants With Abnormal Laboratory Values Reported as Adverse Events at an Incidence of at Least 5%
Laboratory AEs reported at an incidence of at least 5% overall in the following system organ classes (SOCs) are reported: blood and lymphatic system disorders, metabolism and nutrition disorders, investigations, and hepatobiliary disorders. Abnormal laboratory value were assessed as an AE if the value leads to discontinuation or delay in treatment, dose modification, therapeutic intervention, or is considered by the investigator to be a clinically significant change from baseline. A treatment--emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.
Time frame: Up to 30 days after the last dose of study drug (up to 27.4 months)
Number of Participants With Abnormal Vital Signs Reported as Adverse Events
Vital signs (blood pressure, heart rate, and oral temperature) measurements were obtained throughout the study.
Time frame: Up to 30 days after the last dose of study drug (up to 24 months approximately)
Best Overall Response (CR+PR) Based on Investigator's Assessment According to the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
Best overall response is defined as the number of participants with Complete Response (CR) + Partial Response (PR) as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1 for target lesions and assessed by CT or MRI. CR is defined as disappearance of all target lesions and PR is defined as 30% decrease in the sum of the longest diameter (LD) of target lesions. Stable Disease (SD) is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for Progressive Disease, taking as reference the smallest sum LD since the treatment started.
Time frame: At the completion of Cycle 2 and every 2 cycles (every 6 weeks) until Cycle 6 (18 weeks). After Cycle 6 (18 weeks), CT/MRI scans (with contrast) were to be performed every 3 cycles (9 weeks) until PD was documented.
Participants took part in the study at 3 investigative sites in the United States from 25 September 2009 to 01 July 2014.
| Milestone | Dose Escalation Cohort | Part A: Relative Bioavailability OS/PIC (Sequence A) | Part A: Relative Bioavailability PIC/OS (Sequence B) | Part B: OS Food Effect Fed/Fasted (Sequence A) | Part B: OS Food Effect Fasted/Fed (Sequence B) | Part C: ECT Food Effect Fed/Fasted (Sequence A) | Part C: ECT Food Effect Fasted/Fed (Sequence B) |
|---|---|---|---|---|---|---|---|
| Started | 4 | 9 | 10 | 3 | 3 | 12 | 12 |
| Completed | 3 | 7 | 9 | 2 | 3 | 11 | 11 |
| Not completed | 1 | 2 | 1 | 1 | 0 | 1 | 1 |
| Withdrew: Withdrawal by subject | 1 | 2 | 1 | 1 | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
Dose normalized Cmax was obtained using Cmax divided by alisertib dose in milligrams to provide values adjusted to a 1 mg alisertib dose.
| nM/mg | Part A: Alisertib OS | Part A: Alisertib PIC |
|---|---|---|
| Part A: Dose-normalized Cmax (Maximum Observed Concentration) for Estimation of Relative Bioavailability for Alisertib Oral Solution (OS) Versus Powder in Capsule Formulations (PIC) | 58.78 ± 22.583 | 31.40 ± 11.404 |
Dose normalized AUClast was obtained using Cmax divided by alisertib dose in milligrams to provide values adjusted to a 1 mg alisertib dose.
| nM*hr/mg | Part A: Alisertib OS | Part A: Alisertib PIC |
|---|---|---|
| Part A: Dose-normalized AUClast (Area Under the Concentration-Time Curve From Time 0 to Time of the Last Quantifiable Concentration) for Estimation of Relative Bioavailability for Alisertib Oral Solution (OS) Versus Powder in Capsule Formulations (PIC) | 530.18 ± 177.750 | 372.53 ± 145.190 |
Not performed.
No measurements were reported for this outcome.
Not performed.
No measurements were reported for this outcome.
Not performed.
No measurements were reported for this outcome.
Not performed.
No measurements were reported for this outcome.
Not performed.
No measurements were reported for this outcome.
Participants were randomized to receive 50-mg alisertib as an ECT (single, 50-mg strength tablets) under fasted or fed (following a standardized high-fat meal) conditions.
| nM | Part C: Alisertib ECT (Fasted State) | Part C: Alisertib ECT (Fed State) |
|---|---|---|
| Part C: Cmax: Maximum Observed Concentration for Alisertib Administered as an Enteric-Coated Capsule (ECT) With Food Versus Without Food | 1757.9 ± 924.5 | 1401.2 ± 501.0 |
| nM*h | Part C: Alisertib ECT (Fasted State) | Part C: Alisertib ECT (Fed State) |
|---|---|---|
| Part C: AUClast: Area Under the Concentration-Time Curve From Time 0 to Time of the Last Quantifiable Concentration for Alisertib Administered as an Enteric-Coated Capsule (ECT) With Food Versus Without Food | 23928.6 ± 14343.56 | 24135.0 ± 11757.15 |
| nM*h | Part C: Alisertib ECT (Fasted State) | Part C: Alisertib ECT (Fed State) |
|---|---|---|
| Part C: AUC∞: Area Under the Concentration-Time Curve From Time 0 to Infinity, Calculated Using the Observed Value of the Last Quantifiable Concentration for Alisertib Administered as an Enteric-Coated Capsule (ECT) With Food Versus Without Food | 30627.3 ± 21000.29 | 28507.1 ± 15637.50 |
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A Serious Adverse Event (SAE) A serious is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.
| participants | Dose Escalation Cohort | Part A: Relative Bioavailability | Part B: OS Food Effect | Part C: ECT Food Effect |
|---|---|---|---|---|
| AE | 4 | 19 | 6 | 24 |
| SAE | 2 | 4 | 2 | 11 |
Laboratory AEs reported at an incidence of at least 5% overall in the following system organ classes (SOCs) are reported: blood and lymphatic system disorders, metabolism and nutrition disorders, investigations, and hepatobiliary disorders. Abnormal laboratory value were assessed as an AE if the value leads to discontinuation or delay in treatment, dose modification, therapeutic intervention, or is considered by the investigator to be a clinically significant change from baseline. A treatment--emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.
| participants | Dose Escalation Cohort | Part A: Relative Bioavailability | Part B: OS Food Effect | Part C: ECT Food Effect |
|---|---|---|---|---|
| Neutropenia | 3 | 8 | 2 | 21 |
| Leukopenia | 3 | 7 | 2 | 17 |
| Anaemia | 3 | 4 | 2 | 15 |
| Thrombocytopenia | 4 | 3 | 3 | 10 |
| Lymphopenia | 0 | 3 | 0 | 3 |
| Hypomagnesaemia | 0 | 0 | 1 | 7 |
| Hyperglycaemia | 0 | 1 | 1 | 3 |
| Hypokalaemia | 0 | 0 | 1 | 3 |
| White blood cell count decreased | 0 | 0 | 1 | 5 |
| Aspartate aminotransferase increased | 1 | 0 | 0 | 6 |
| Gamma-glutamyltransferase increased | 0 | 1 | 0 | 2 |
| Lymphocyte count decreased | 0 | 0 | 0 | 3 |
| Neutrophil count decreased | 0 | 1 | 0 | 2 |
| Hyperbilirubinaemia | 1 | 0 | 0 | 3 |
Vital signs (blood pressure, heart rate, and oral temperature) measurements were obtained throughout the study.
| participants | Dose Escalation Cohort | Part A: Relative Bioavailability | Part B: OS Food Effect | Part C: ECT Food Effect |
|---|---|---|---|---|
| Hypertension | 1 | 0 | 1 | 1 |
| Hypotension | 0 | 1 | 1 | 0 |
| Tachycardia | 1 | 1 | 1 | 0 |
| Sinus bradycardia | 0 | 0 | 0 | 1 |
Best overall response is defined as the number of participants with Complete Response (CR) + Partial Response (PR) as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1 for target lesions and assessed by CT or MRI. CR is defined as disappearance of all target lesions and PR is defined as 30% decrease in the sum of the longest diameter (LD) of target lesions. Stable Disease (SD) is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for Progressive Disease, taking as reference the smallest sum LD since the treatment started.
| participants | Dose Escalation Cohort | Part A: Relative Bioavailability OS/PIC (Sequence A) | Part A: Relative Bioavailability PIC/OS (Sequence B) | Part B: OS Food Effect Fed/Fasted (Sequence A) | Part B: OS Food Effect Fasted/Fed (Sequence B) | Part C: ECT Food Effect Fed/Fasted (Sequence A) | Part C: ECT Food Effect Fasted/Fed (Sequence B) |
|---|---|---|---|---|---|---|---|
| Best Overall Response of CR or PR | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Best Overall Response of Stable Disease | 0 | 1 | 5 | 2 | 1 | 6 | 6 |
Collected over Up to 30 days after the last dose of study drug (up to 27.4 months approximately). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dose Escalation Cohort | — | 2/4 (50%) | 4/4 (100%) |
| Part A: Relative Bioavailability | — | 4/19 (21.1%) | 19/19 (100%) |
| Part B: OS Food Effect | — | 2/6 (33.3%) | 6/6 (100%) |
| Part C: ECT Food Effect | — | 11/24 (45.8%) | 24/24 (100%) |
| Event | Dose Escalation Cohort | Part A: Relative Bioavailability | Part B: OS Food Effect | Part C: ECT Food Effect |
|---|---|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 1/4 | 0/19 | 0/6 | 1/24 |
| HyperbilirubinaemiaHepatobiliary disorders | 1/4 | 0/19 | 0/6 | 0/24 |
| DehydrationMetabolism and nutrition disorders | 1/4 | 1/19 | 0/6 | 0/24 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/4 | 1/19 | 1/6 | 2/24 |
| FatigueGeneral disorders | 0/4 | 0/19 | 1/6 | 0/24 |
| PainGeneral disorders | 0/4 | 0/19 | 1/6 | 0/24 |
| SepsisInfections and infestations | 0/4 | 0/19 | 1/6 | 0/24 |
| VomitingGastrointestinal disorders | 0/4 | 1/19 | 0/6 | 1/24 |
| HydronephrosisRenal and urinary disorders | 0/4 | 1/19 | 0/6 | 1/24 |
| NauseaGastrointestinal disorders | 0/4 | 1/19 | 0/6 | 0/24 |
| Event | Dose Escalation Cohort | Part A: Relative Bioavailability | Part B: OS Food Effect | Part C: ECT Food Effect |
|---|---|---|---|---|
| StomatitisGastrointestinal disorders | 4/4 | 7/19 | 5/6 | 6/24 |
| ThrombocytopeniaBlood and lymphatic system disorders | 4/4 | 3/19 | 3/6 | 7/24 |
| LeukopeniaBlood and lymphatic system disorders | 3/4 | 7/19 | 2/6 | 13/24 |
| AnaemiaBlood and lymphatic system disorders | 3/4 | 4/19 | 2/6 | 13/24 |
| FatigueGeneral disorders | 3/4 | 12/19 | 4/6 | 11/24 |
| NeutropeniaBlood and lymphatic system disorders | 2/4 | 8/19 | 2/6 | 17/24 |
| DiarrhoeaGastrointestinal disorders | 0/4 | 11/19 | 1/6 | 13/24 |
| AlopeciaSkin and subcutaneous tissue disorders | 1/4 | 5/19 | 1/6 | 13/24 |
| NauseaGastrointestinal disorders | 2/4 | 10/19 | 2/6 | 9/24 |
| PyrexiaGeneral disorders | 2/4 | 2/19 | 2/6 | 1/24 |
Safety population is defined as all participants who receive any amount of alisertib. Efficacy analysis included all participants who had a baseline response assessment and at least one on-study response assessment.
| Age, Continuous(years) | Dose Escalation Cohort | Part A: Relative Bioavailability OS/PIC (Sequence A) | Part A: Relative Bioavailability PIC/OS (Sequence B) | Part B: OS Food Effect Fed/Fasted (Sequence A) | Part B: OS Food Effect Fasted/Fed (Sequence B) | Part C: ECT Food Effect Fed/Fasted (Sequence A) | Part C: ECT Food Effect Fasted/Fed (Sequence B) | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 58.3 (57 to 59) | 54.6 (20 to 71) | 54.0 (36 to 70) | 51.7 (31 to 64) | 57.7 (53 to 61) | 57.4 (39 to 72) | 55.2 (46 to 69) | 55.5 (20 to 72) |
| Sex: Female, Male(Participants) | Dose Escalation Cohort | Part A: Relative Bioavailability OS/PIC (Sequence A) | Part A: Relative Bioavailability PIC/OS (Sequence B) | Part B: OS Food Effect Fed/Fasted (Sequence A) | Part B: OS Food Effect Fasted/Fed (Sequence B) | Part C: ECT Food Effect Fed/Fasted (Sequence A) | Part C: ECT Food Effect Fasted/Fed (Sequence B) | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 3 | 2 | 5 | 1 | 1 | 7 | 9 | 28 |
| Male | 1 | 7 | 5 | 2 | 2 | 5 | 3 | 25 |
| Race/Ethnicity, Customized(participants) | Dose Escalation Cohort | Part A: Relative Bioavailability OS/PIC (Sequence A) | Part A: Relative Bioavailability PIC/OS (Sequence B) | Part B: OS Food Effect Fed/Fasted (Sequence A) | Part B: OS Food Effect Fasted/Fed (Sequence B) | Part C: ECT Food Effect Fed/Fasted (Sequence A) | Part C: ECT Food Effect Fasted/Fed (Sequence B) | Total |
|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 2 | 0 | 1 | 2 | 1 | 6 |
| Not Hispanic or Latino | 4 | 9 | 8 | 3 | 2 | 10 | 11 | 47 |
| Race/Ethnicity, Customized(participants) | Dose Escalation Cohort | Part A: Relative Bioavailability OS/PIC (Sequence A) | Part A: Relative Bioavailability PIC/OS (Sequence B) | Part B: OS Food Effect Fed/Fasted (Sequence A) | Part B: OS Food Effect Fasted/Fed (Sequence B) | Part C: ECT Food Effect Fed/Fasted (Sequence A) | Part C: ECT Food Effect Fasted/Fed (Sequence B) | Total |
|---|---|---|---|---|---|---|---|---|
| White | 4 | 8 | 9 | 3 | 2 | 12 | 11 | 49 |
| Black or African American | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 3 |
| Asian | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Region of Enrollment(participants) | Dose Escalation Cohort | Part A: Relative Bioavailability OS/PIC (Sequence A) | Part A: Relative Bioavailability PIC/OS (Sequence B) | Part B: OS Food Effect Fed/Fasted (Sequence A) | Part B: OS Food Effect Fasted/Fed (Sequence B) | Part C: ECT Food Effect Fed/Fasted (Sequence A) | Part C: ECT Food Effect Fasted/Fed (Sequence B) | Total |
|---|---|---|---|---|---|---|---|---|
| United States | 4 | 9 | 10 | 3 | 3 | 12 | 12 | 53 |
| Height(cm) | Dose Escalation Cohort | Part A: Relative Bioavailability OS/PIC (Sequence A) | Part A: Relative Bioavailability PIC/OS (Sequence B) | Part B: OS Food Effect Fed/Fasted (Sequence A) | Part B: OS Food Effect Fasted/Fed (Sequence B) | Part C: ECT Food Effect Fed/Fasted (Sequence A) | Part C: ECT Food Effect Fasted/Fed (Sequence B) | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 167.7 (163 to 175) | 172.6 (154 to 185) | 172.8 (160 to 188) | 160.3 (157 to 163) | 169.1 (159 to 182) | 169.2 (159 to 179) | 160.5 (152 to 169) | 167.4 (152 to 188) |
| Weight(kg) | Dose Escalation Cohort | Part A: Relative Bioavailability OS/PIC (Sequence A) | Part A: Relative Bioavailability PIC/OS (Sequence B) | Part B: OS Food Effect Fed/Fasted (Sequence A) | Part B: OS Food Effect Fasted/Fed (Sequence B) | Part C: ECT Food Effect Fed/Fasted (Sequence A) | Part C: ECT Food Effect Fasted/Fed (Sequence B) | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 72.7 (66 to 80) | 85.5 (68 to 118) | 81.4 (65 to 120) | 66.3 (45 to 99) | 77.7 (59 to 99) | 73.0 (45 to 98) | 66.1 (43 to 101) | 74.7 (43 to 120) |
| Body Surface Area (BSA)(m^2) | Dose Escalation Cohort | Part A: Relative Bioavailability OS/PIC (Sequence A) | Part A: Relative Bioavailability PIC/OS (Sequence B) | Part B: OS Food Effect Fed/Fasted (Sequence A) | Part B: OS Food Effect Fasted/Fed (Sequence B) | Part C: ECT Food Effect Fed/Fasted (Sequence A) | Part C: ECT Food Effect Fasted/Fed (Sequence B) | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 1.84 (1.7 to 2.0) | 2.02 (1.8 to 2.4) | 1.97 (1.7 to 2.5) | 1.69 (1.4 to 2.1) | 1.90 (1.6 to 2.2) | 1.82 (1.4 to 2.2) | 1.68 (1.4 to 2.1) | 1.85 (1.4 to 2.5) |
Ran from Sep 2009 to primary completion in Dec 2011, 27 months.
Results were first posted in Mar 2019, 7 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MLN 8237
Millennium Pharmaceuticals, Inc. →